B. Vaughan Hudson

发表

Systemic disturbance in Hodgkin's disease and its relation to histopathology and prognosis (BNLI report No. 30).

K. Maclennan, M. Easterling, A. Jelliffe, 1987, Clinical radiology.

Impact of high-dose salvage therapy (BEAM) on overall survival in younger patients with advanced large-cell lymphomas entered into BNLI trials.

D. Linch, G. Vaughan Hudson, L. Anderson, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease: a British National Lymphoma Investigation pilot study.

M. Williams, E. Bessell, N. Bates, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-Hodgkin's lymphoma arising in patients treated for Hodgkin's disease in the BNLI: a 20-year experience. British National Lymphoma Investigation.

K. Maclennan, G. Vaughan Hudson, B. Vaughan Hudson, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Diagnosis and grading of nodular sclerosing Hodgkin's disease: a study of 2190 patients.

K. Maclennan, G. Vaughan Hudson, B. Vaughan Hudson, 1992, International review of experimental pathology.

Late mortality in young BNLI patients cured of Hodgkin's disease.

D. Linch, G. Vaughan Hudson, L. Anderson, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study.

D C Linch, K. Maclennan, D. Cunningham, 1996, Blood.

LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial.

K. Maclennan, J. Haybittle, D. Linch, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The presentation haemoglobin level in 1103 patients with Hodgkin's disease (BNLI report no. 21).

K. Maclennan, J. Haybittle, M. Easterling, 1983, Clinical radiology.

The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin's disease: an analysis of 271 non-laparotomised cases (BNLI report no. 22).

K. Maclennan, M. Easterling, A. Jelliffe, 1983, Clinical radiology.

Primary gastrointestinal non-Hodgkin's lymphoma: a review of 175 British National Lymphoma Investigation cases.

K. Maclennan, M. Leyland, G. Vaughan Hudson, 1993, British Journal of Cancer.

The prognostic influence of mediastinal bulk in pathological stage IIA Hodgkin's disease treated initially with radiotherapy.

K. Maclennan, D. Linch, S. Schey, 1989, Clinical oncology (Royal College of Radiologists (Great Britain)).

Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy.

K. Maclennan, D. Linch, G. Vaughan Hudson, 1994, British Journal of Cancer.

Hybrid LOPP/EVA is not better than LOPP alternating with EVAP: a prematurely terminated British National Lymphoma Investigation randomized trial.

K. Maclennan, D. Linch, B. Hancock, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results.

K. Maclennan, J. Haybittle, B. Hancock, 1991, British Journal of Cancer.

Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation.

D. Linch, S. Devereux, G. Vaughan Hudson, 1990, BMJ.

Selective peripheral blood eosinophilia associated with survival advantage in Hodgkin's disease (BNLI Report No 31). British National Lymphoma Investigation.

K. Maclennan, E. Macintyre, D. Linch, 1987, Journal of clinical pathology.

The prognostic significance of age in Hodgkin's disease: examination of 1500 patients (BNLI report no. 23).

K. Maclennan, J. Haybittle, M. Easterling, 1983, Clinical radiology.

Long-term survival in Hodgkin's disease patients. A comparison of relative survival in patients in trials and those recorded in population-based cancer registries.

A. Swerdlow, J. Estève, P. Roy, 2000, European journal of cancer.

A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report.

K. Maclennan, W. Gregory, P. Hoskin, 1996, British Journal of Cancer.

Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy.

K. Maclennan, A. Swerdlow, A. Douglas, 1993, British Journal of Cancer.

The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non‐intensive therapy by the British National Lymphoma Investigation Group

S. Pittaluga, C. de Wolf‐Peeters, D. Linch, 1997, British journal of haematology.

Incidence and clinical importance of bone marrow eosinophilia in Hodgkin's disease (BNLI Report No 29). British National Lymphoma Investigation.

E. Macintyre, D. Linch, A. Jelliffe, 1987, Journal of clinical pathology.